Glenmark Pharmaceuticals Ltd.’s rhinitis therapy Ryaltris (olopatadine HCl/mometasone furoate) has been approved in Australia, the first market where the fixed‐dose combination nasal spray is expected to be launched this year.
Glenmark To Debut Ryaltris In Australia
Rhinitis Therapy Gets TGA Nod For Launch In 2020
Glenmark ended 2019 on a buoyant note, with its rhinitis therapy getting the go-ahead in Australia. Though not seen as a huge commercial opportunity in the island continent, the clearance augurs well for the product’s overall trajectory.
